Micro Invasive Glaucoma Surgery (MIGS) Devices Market research report provides outstanding business solutions with which overcoming business challenges become easy. The report analyses the market situation which may change in the coming years. Also, the report studies general market conditions, estimates client company’s market share and possible sales volume, figure out the probable market for a new product to be launched and discover the most appropriate method for the distribution of certain product. The Micro Invasive Glaucoma Surgery (MIGS) Devices Market report also covers detailed analysis of top players. This market research report offers an exhaustive summary of product specification, technology, product type and production analysis considering major factors such as revenue, cost, gross and gross margin.

 

Data Bridge Market Research analyses that the micro invasive glaucoma surgery (MIGS) devices market is expected to reach the value of USD 5,995.46 million by 2029, at a CAGR of 33.3% during the forecast period.

 

Download Sample PDF Copy of this Report to understand structure of the complete report (Including Full TOC, Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-micro-invasive-glaucoma-surgery-migs-devices-market

 

MIGS stands for micro invasive glaucoma surgery, which helps treat glaucoma. It is a breakthrough technology in the treatment of mild to moderate glaucoma. It is an alternative to the medications given earlier and it also prevents the complications of conventional surgery. These procedures are used to lower the intra-ocular pressure of the eye to avoid damage to the optic nerve. These procedures are safer and have a very rapid recovery time compared to conventional surgery. The various MIGS devices implanted are shunts and stents to lower the IOP.

 

Some of the major players operating in the micro invasive glaucoma surgery (MIGS) devices market are AbbVie, BVI, Ellex, Glaukos Corporation, Johnson and Johnson, Alcon, Microsurgical technology, New World Medical, Santen Pharmaceutical, Nova Eye Medical Limited, Belkin Vision and Sight Scientific among others.

 

A significant health-related issue among the elderly is vision loss. According to the American Academy of Family Physicians, by age 65, one in three people suffer from vision-reducing eye disease. The elderly population is increasing rapidly. Therefore this creates a demand for advanced technologies to treat glaucoma amongst older adults. Hence, an increase in the geriatric population is a driver for the market.

The cause of irreversible global blindness is majorly glaucoma. A glaucoma is a group of eye disorders that have very little to no symptoms in the initial stage but afterward lead to damage of optic nerves, which can lead to vision loss or blindness. The prevalence of glaucoma has been increasing.

Therefore this creates a demand for MIGS devices; hence an increasing incidence of glaucoma is expected to act as a driver for the market.

According to WHO, at least 2.2 billion people have visual impairment and blindness, out of which at least 1 billion have a vision impairment that could have been prevented. To prevent these, the government of several countries across the globe have taken initiatives. This creates a demand for advanced treatments such as micro-invasive glaucoma surgery, which boosts the MIGS device market. Hence, it is expected to act as a driver for the market.

Glaucoma is a severe eye disease that can lead to vision loss if not controlled. It generally does not lead to blindness as it can be controlled by modern treatment and many options for preventing further damage. With the increased scientific developments, there has been a revolutionary change in the treatment of glaucoma. With the advent of micro-invasive glaucoma surgery, there is a paradigm shift in medicine as it can help in the treatment of glaucoma at an early stage and avoid the dependency on filtration surgeries like trabeculectomy. This also overcomes the risks associated with these incisional surgeries. There are various advancements in the treatment of glaucoma with MIGS.

 

There are at least 7 regulations that any device manufacturer must completely fulfill in the U.S., namely Establishment Registration & Medical Device Listing, Premarket Notification 510(k), Premarket Approval (PMA)(only for class three devices), Investigational Device Exemption (IDE) for clinical studies, Quality System (QS) regulation, Labeling requirements and Medical Device Reporting (MDR). These highest-risk devices need a more stringent premarket application regulatory process to demonstrate valid evidence of safety and efficacy. Lengthy timelines result in delayed access, which might restrict the market for MIGS devices.

 

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Micro Invasive Glaucoma Surgery (MIGS) Devices Market Landscape

Part 04: Micro Invasive Glaucoma Surgery (MIGS) Devices Market Sizing

Part 05: Micro Invasive Glaucoma Surgery (MIGS) Devices Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Get the Full Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-micro-invasive-glaucoma-surgery-migs-devices-market

 

 

An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.

 

Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.

 

Data Bridge Market Research

US: +1 888 387 2818

United Kingdom: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: – sopan.gedam@databridgemarketresearch.com